The expression of YWHAZ and NDRG1 predicts aggressive outcome in human prostate cancer.
14-3-3 Proteins
/ metabolism
Adenocarcinoma
/ metabolism
Adult
Aged
Biomarkers, Tumor
/ metabolism
Cell Cycle Proteins
/ metabolism
Humans
Intracellular Signaling Peptides and Proteins
/ metabolism
Male
Mass Spectrometry
Middle Aged
Prostatic Hyperplasia
/ metabolism
Prostatic Neoplasms
/ metabolism
Proteome
Risk Assessment
Journal
Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179
Informations de publication
Date de publication:
22 01 2021
22 01 2021
Historique:
received:
11
06
2020
accepted:
16
12
2020
entrez:
23
1
2021
pubmed:
24
1
2021
medline:
29
6
2021
Statut:
epublish
Résumé
Some prostate cancers (PCas) are histo-pathologically grouped within the same Gleason Grade (GG), but can differ significantly in outcome. Herein, we aimed at identifying molecular biomarkers that could improve risk prediction in PCa. LC ESI-MS/MS was performed on human PCa and benign prostatic hyperplasia (BPH) tissues and peptide data was integrated with omic analyses. We identified high YWHAZ and NDRG1 expression to be associated with poor PCa prognosis considering all Gleason scores (GS). YWHAZ and NDRG1 defined two subpopulations of PCa patients with high and intermediate risk of death. Multivariable analyses confirmed their independence from GS. ROC analysis unveiled that YWHAZ outperformed GS beyond 60 months post-diagnosis. The genomic analysis of PCa patients with YWHAZ amplification, or increased mRNA or protein levels, revealed significant alterations in key DNA repair genes. We hereby state the relevance of YWHAZ in PCa, showcasing its role as an independent strong predictor of aggressiveness.
Identifiants
pubmed: 33483585
doi: 10.1038/s42003-020-01645-2
pii: 10.1038/s42003-020-01645-2
pmc: PMC7822895
doi:
Substances chimiques
14-3-3 Proteins
0
Biomarkers, Tumor
0
Cell Cycle Proteins
0
Intracellular Signaling Peptides and Proteins
0
N-myc downstream-regulated gene 1 protein
0
Proteome
0
YWHAZ protein, human
0
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
103Subventions
Organisme : NCI NIH HHS
ID : U01 CA224044
Pays : United States
Références
PLoS One. 2011 Feb 11;6(2):e16833
pubmed: 21347291
N Engl J Med. 2009 Mar 26;360(13):1320-8
pubmed: 19297566
BMC Genomics. 2013 Oct 08;14:690
pubmed: 24103217
Int J Oncol. 2013 Aug;43(2):365-74
pubmed: 23708710
Eur Urol. 2011 Jan;59(1):96-105
pubmed: 20980098
Int J Radiat Oncol Biol Phys. 1987 Jul;13(7):1007-12
pubmed: 3597142
Urol Oncol. 2015 Apr;33(4):163.e15-23
pubmed: 25575715
J Urol. 2014 Jun;191(6):1743-8
pubmed: 24333241
BJU Int. 2009 Jun;103(12):1647-54
pubmed: 19154461
PLoS One. 2013 Dec 27;8(12):e84295
pubmed: 24386364
Clin Cancer Res. 2010 Jan 1;16(1):56-64
pubmed: 20028754
Cancer Biomark. 2018;21(4):869-874
pubmed: 29400662
Eur Urol. 2017 Mar;71(3):417-425
pubmed: 27590317
World J Urol. 2016 Apr;34(4):485-93
pubmed: 26194612
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1632-4
pubmed: 26189769
Mol Cancer. 2012 Sep 20;11:71
pubmed: 22992343
PLoS One. 2008;3(5):e2318
pubmed: 18846227
Int J Radiat Oncol Biol Phys. 1980 Sep;6(9):1121-6
pubmed: 7462066
Eur Urol. 2014 Mar;65(3):534-42
pubmed: 23201468
PLoS One. 2013 Jul 04;8(7):e67687
pubmed: 23861782
Carcinogenesis. 2008 Jan;29(1):2-8
pubmed: 17916902
Prostate. 2007 Apr 1;67(5):557-71
pubmed: 17221842
Clin Cancer Res. 2012 Oct 15;18(20):5617-27
pubmed: 22904106
Nat Rev Urol. 2012 Aug;9(8):418-28
pubmed: 22710668
Mol Oncol. 2017 Jun;11(6):655-669
pubmed: 28371345
Prostate Cancer Prostatic Dis. 2014 Dec;17(4):310-4
pubmed: 25156059
Urol Pract. 2017 Jul;4(4):315-321
pubmed: 29104903
J Urol. 1983 Feb;129(2):309-11
pubmed: 6834496
Cancer Cell. 2016 Jan 11;29(1):104-116
pubmed: 26766592
Stat Med. 2013 Dec 30;32(30):5381-97
pubmed: 24027076
Nucleic Acids Res. 2016 Jan 4;44(D1):D944-51
pubmed: 26602695
BMC Med Genomics. 2010 Mar 16;3:8
pubmed: 20233430
Prostate. 2015 Jan;75(1):103-11
pubmed: 25327361
J Proteome Res. 2014 Feb 7;13(2):915-24
pubmed: 24328109
Hum Pathol. 2010 Feb;41(2):214-22
pubmed: 19800102
PLoS One. 2012;7(12):e51862
pubmed: 23251644
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436
pubmed: 31061129
Cancer. 1986 Oct 15;58(8):1770-8
pubmed: 3756799
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Curr Treat Options Oncol. 2018 Feb 8;19(2):8
pubmed: 29423762
Int J Oncol. 2009 May;34(5):1403-9
pubmed: 19360353
BMJ. 2009 Sep 24;339:b3601
pubmed: 19778971
Br J Cancer. 2013 Apr 2;108(6):1324-31
pubmed: 23422756
Eur Urol. 2012 May;61(5):1019-24
pubmed: 22336380
EBioMedicine. 2015 Jul 29;2(9):1133-44
pubmed: 26501111
Tumour Biol. 2013 Jun;34(3):1337-47
pubmed: 23504524
J Urol. 2011 Dec;186(6):2221-7
pubmed: 22014803
Int J Oncol. 2003 Apr;22(4):779-86
pubmed: 12632068
Genome Biol. 2007;8(9):R183
pubmed: 17784955
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Neoplasia. 2004 Jan-Feb;6(1):1-6
pubmed: 15068665
Prostate. 2010 Jan 1;70(1):10-6
pubmed: 19708043